Malignant degeneration of Barrett's esophagus: The role of the Ki-67 proliferation fraction, expression of E-cadherin and p53

Diseases of the Esophagus

Volumn 17, Issue 4, 2004, Pages 322-327

  Feith, M ^a   Stein, H J ^b   Mueller, J ^b   Siewert, J R ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

Adhesion molecules; Barrett's esophagus; Cell proliferation; Esophageal cancer

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; UVOMORULIN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; COLUMNAR EPITHELIUM; CONTROLLED STUDY; CORRELATION FUNCTION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SQUAMOUS EPITHELIUM;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; BIOPSY; CADHERINS; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12344253628     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2004.00434.x     Document Type: Article

References (28)

1. Cameron A J, Ott B J, Payne W S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9.
2. Hoelscher A H, Bollschweiler E, Schneider P M, Siewert J R. Early adenocarcinoma in Barrett' esophagus. Br J Surg 1997; 84: 1470-3.
3. Stein H J, Feith M, Siewert J R. Malignant degeneration of Barrett's esophagus: clinical point of view. Recent Results Cancer Res 2000; 155: 42-53.
4. Devesa S S, Blot W J, Fraumeni J F Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
5. Hameeteman W, Tytgat G N, Houthoff H J, van den Tweel J G. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-56.
6. Heitmiller R F, Redmond M, Hamilton S R. Barrett's esophagus with high-grade dyspalsia an indication for prophylactic esophagectomy. Ann Surg 1996; 224: 66-71.
7. Rice T W, Goldblum J R, Falk G W, Tubbs R R, Kirby T J, Casey G. p53 Immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg 1994; 108: 1132-7.
8. Schneider P M, Casson A G, Levin B, et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996; 111: 323-31.
9. Younes M, Ertan A, Lechago L V, Somoano J R, Lechago J. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997; 42: 697-701.
10. Hollstein M, Sidrandsky D, Vogelstein B, Harris C C. p53 Mutations in human cancers. Science 1991; 253: 49-53.
11. Nigro J M, Baker S J, Preisinger A C, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705-8.
12. Doki Y, Shiozaki H, Tahara H, et al. Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 1993; 53: 3421-6.
13. Swami S, Kumble S, Triadafilopoulos G. E-Cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma. An immunohistochemical immunoblot study. Am J Gastroenterol 1995; 90: 1808-13.
14. Becker K F, Atkinson M J, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54: 3845-52.
15. Becker K F, Hofler H. Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst 1995; 87: 1082-4.
16. Birchmeier W, Behrens J, Weidner K M, Frixen U H, Schipper J. Dominant and recessive genes involved in tumor cell adhesion. Curr Opin Cell Biol 1991; 3: 832-40.
17. Crossin K L. Cell adhesion molecules in embryogenesis and disease. Ann N Y Acad Sci 1991; 615: 172-86.
18. Frixen U H, Behrens J, Sachs M, et al. E-cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-85.
19. Shimoyama Y, Hirohashi S. Expression of E- and P-cadherin in gastric carcinomas. Cancer Res 1991; 51: 2185-92.
20. Gerdes J, Lemke H, Baisch H, Wacker H H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-15.
21. Gerdes J, Lelle R J, Pickartz H, et al. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 1986; 38: 977-80.
22. Hong M K, Laskin W B, Herman B E, et al. Expansion of the Ki-67 Proliferative compartment correlates with degree of dyspalsia in Barrett's esophagus. Cancer 1995; 75: 423-9.
23. Johnston P G, O'Brien M J, Dervan P A, Carney D N. Immunhistochemical analysis of cell kinetic parameters in colonic adenocarcinomas, adenomas, and normal mucosa. Hum Pathol 1989; 20: 696-700.
24. Mulder A H, VanHootegem J C S P, Sylvester R et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle related nuclear antigen (Ki-67). J Pathol 1992; 166: 37-43.
25. Ramires M, David L, Leitao D, Seixas M, Sansonetty F, Sobrinho-Simoes M. Ki-67 labelling index in gastric carcinomas. An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse-type carcinomas. J Pathol 1997; 182: 62-7.
26. Natsugoe S, Mueller J, Stein H J, Feith M, Höfler H, Siewert J R. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma. Cancer 1998; 83: 858-66.
27. Stein H J, Panel of Experts. Esophageal cancer: screening and surveillance. Results of a consensus conference. Dis Esophagus 1996; 9: 3-19.
28. Siewert J R, Stein H J. Barrett's cancer: Indications, extent and results of surgical resection. Sem Surg Oncol 1997; 13: 245-52.